Atherosclerosis: Open Access
Open Access

Atherosclerosis, characterized as a chronic inflammatory disease of the arteries, continues to pose a significant global health burden by being a leading cause of cardiovascular morbidity and mortality. Over the years, researchers and healthcare professionals have made significant progress in unraveling the pathophysiological mechanisms that underlie this complex condition [1-4]. Despite this progress, atherosclerosis remains a formidable challenge due to its multifactorial nature, involving intricate interactions between genetic, environmental, and lifestyle factors. With advancements in scientific discoveries and cutting-edge technologies, the field of atherosclerosis research is experiencing a transformative phase. New insights and emerging trends have the potential to revolutionize our understanding of the disease and pave the way for innovative treatments and prevention strategies.

Cellular senescence: a game-changer in atherosclerosis: One of the most promising and intriguing trends in atherosclerosis research is the exploration of cellular senescence’s role in disease development. Cellular senescence, a state of irreversible cell cycle arrest, has recently emerged as a crucial player in atherosclerosis pathogenesis. Senescent cells accumulate in atherosclerotic plaques, secreting a range of pro-inflammatory molecules and promoting plaque instability. Understanding the factors that trigger cellular senescence and identifying senescence-specific therapeutic targets open up exciting possibilities for halting disease progression [5]. Innovative therapies that specifically target senescent cells (senolytics) or modulate their inflammatory secretome (senomorphics) have shown promise in preclinical studies, offering new avenues for the development of antiatherosclerotic treatments.

Microbiome and atherosclerosis: a gut feeling: The gut microbiome, a vast community of microbes residing in the human gastrointestinal tract, has gained significant attention for its potential impact on human health. Recent studies suggest that the gut microbiome plays a pivotal role in modulating systemic inflammation and lipid metabolism, potentially influencing atherosclerosis development. Perturbations in the gut microbial composition have been linked to cardiovascular risk factors and atherogenesis [6,7]. Researchers are investigating the intricate crosstalk between the gut microbiome and the arterial wall, opening up exciting prospects for novel therapeutic interventions. Manipulating the gut microbiota through dietary interventions, probiotics, or fecal microbiota transplantation could emerge as novel strategies for reducing atherosclerotic burden and cardiovascular risk.

Precision medicine in atherosclerosis: tailoring therapies to individuals: The era of precision medicine has dawned, allowing healthcare providers to tailor treatments to individual patients based on their unique genetic makeup, lifestyle, and risk factors. In the context of atherosclerosis, high-density genotyping and polygenic risk scores have the potential to predict disease risk more accurately and identify specific therapeutic targets. Precision medicine enables a personalized approach to atherosclerosis management, optimizing therapeutic interventions and potentially improving patient outcomes [8]. Integrating genomic data into clinical practice may lead to more effective risk stratification, early diagnosis, and targeted therapies.

Beyond lipid-lowering: inflammation as a therapeutic target: While lipid-lowering therapies, such as statins, have proven effective in reducing cardiovascular risk, recent studies have emphasized the role of inflammation in atherosclerosis pathogenesis. Targeting inflammatory pathways, including interleukin-1β, has shown promise in clinical trials. This emerging trend highlights the need to broaden our therapeutic arsenal beyond lipid modulation and underscores the potential benefits of combination therapies that address both lipid and inflammatory pathways.

As we delve deeper into the intricate mechanisms of atherosclerosis, promising avenues for diagnosis and treatment are becoming apparent [9,10]. Cellular senescence, gut microbiome interactions, precision medicine, and inflammation-targeted therapies have emerged as trending topics in atherosclerosis research. By embracing these novel insights and fostering interdisciplinary collaborations, we can pave the way for transformative advancements in managing this life-threatening condition. As researchers and clinicians work together, the future of atherosclerosis treatment looks brighter than ever, offering hope for a world with fewer cardiovascular burdens and improved quality of life for millions of individuals globally.

1. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, et al. (2002) Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105:1541-1544.

Indexed at, Google Scholar, Crossref

2. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, et al. (2011) Clearance of p16Ink4a-positive senescent cells delays ageing associated disorders. Nature 479:232-236.

Indexed at, Google Scholar, Crossref

3. Coppe JP, Desprez PY, Krtolica A, Campisi J (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5:99-118.

Indexed at, Google Scholar, Crossref

4. Lassegue B, San Martin A, Griendling KK (2012) Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 110:1364-1390.

Indexed at, Google Scholar, Crossref

5. Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell strains. Exp Cell Res 25:585-621.

Indexed at, Google Scholar, Crossref

6. Fuster JJ, Andres V (2006) Telomere biology and cardiovascular disease. Circ Res 99:1167-1180.

Indexed at, Google Scholar, Crossref

7. Erusalimsky JD, Kurz DJ (2005) Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Exp Gerontol 40:634-642.

Indexed at, Google Scholar, Crossref

8. Beattie JH, Gordon MJ, Duthie SJ, McNeil CJ, Horgan GW, et al. (2012) Suboptimal dietary zinc intake promotes vascular inflammation and atherogenesis in a mouse model of atherosclerosis. Mol Nutr Food Res 56:1097-1105.

Indexed at, Google Scholar, Crossref

9. Black RE, Allen LH, Bhutta ZA, Caulfield LE, De Onis M, et al. (2008) Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 371:243-260.

Indexed at, Google Scholar, Crossref

10. Little PJ, Bhattacharya R, Moreyra AE, Korichneva IL (2010) Zinc and cardiovascular disease. Nutrition 26:1050-1057.

Indexed at, Google Scholar, Crossref